Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

338
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
338
Analgesia and Pain Management01:25

Analgesia and Pain Management

660
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
660
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

293
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
293
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

1.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.1K
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

247
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
247
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

214
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
214

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Multisite Trial Assessing Efficacy and Safety.

Alcohol, clinical & experimental research·2026
Same author

Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff.

Drug and alcohol review·2026
Same author

Increased dementia diagnosis and workup in primary care with a bilingual screening tool integrated in the electronic health record.

Journal of Alzheimer's disease : JAD·2026
Same author

Safety of Intravenous Methamphetamine in Patients Taking Mirtazapine: A Two-Site Phase 1b Randomized Controlled Trial.

Journal of clinical psychopharmacology·2026
Same author

Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Jul 21, 2025

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.3K

Creating a standard inpatient opioid withdrawal protocol.

Ariana Abid1,2, Steve Shoptaw1, Michelle Bholat1

  • 1Family Medicine, UCLA ACCESS, Los Angeles, CA, USA.

Mededpublish (2016)
|July 27, 2023
PubMed
Summary

Hospitals can reduce costs by treating hospitalized patients with opioid use disorder (OUD) using a new buprenorphine protocol. This evidence-based approach addresses opioid withdrawal during inpatient care, improving patient outcomes.

Keywords:
addictionbuprenorphineinpatientopioidoverdoseswithdrawal

More Related Videos

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats
04:11

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats

Published on: November 6, 2018

17.0K
A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence
08:05

A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence

Published on: March 23, 2022

2.6K

Related Experiment Videos

Last Updated: Jul 21, 2025

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.3K
A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats
04:11

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats

Published on: November 6, 2018

17.0K
A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence
08:05

A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence

Published on: March 23, 2022

2.6K

Area of Science:

  • Addiction Medicine
  • Hospital Administration
  • Pharmacology

Background:

  • Opioid Use Disorder (OUD) treatment is underutilized in US hospitals.
  • Untreated opioid withdrawal leads to high healthcare costs and patient departures.
  • Buprenorphine is a safe and effective medication for OUD.

Purpose of the Study:

  • To develop and implement a practical opioid withdrawal protocol using buprenorphine.
  • To address opioid withdrawal in hospitalized patients with a primary medical condition.
  • To reduce healthcare costs associated with untreated opioid withdrawal.

Main Methods:

  • Developed a protocol with electronic medical record order sets.
  • Utilized the Clinical Opiate Withdrawal Scale for monitoring.
  • Integrated physician, nursing, pharmacy, and case management roles.

Main Results:

  • The protocol facilitates seamless care for opioid withdrawal during inpatient treatment.
  • Nursing plays a key role in monitoring and medication administration.
  • Pharmacy and case management ensure appropriate dosing and safe discharge.

Conclusions:

  • Challenges include inconsistent addiction education and limited outpatient buprenorphine access.
  • Standardized protocols can improve care for hospitalized OUD patients.
  • Further research needed on overcoming implementation barriers.